Pacific Ethanol, Inc. (Nasdaq:PEIX), the leading producer and marketer of low-carbon renewable fuels in the Western United States, announced it has priced an underwritten offering of 1,750,000 shares of its common stock at a price to the public of $16.00 per share, for gross offering proceeds of $28.0 million. Lazard Capital Markets LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering.Pacific Ethanol Inc (NASDAQ:PEIX) shares after opening at $16.81 moved to $17.86 on last trade day and at the end of the day closed at $15.76. Company price to sales ratio in past twelve months was calculated as 0.28 and price to cash ratio as 48.77. Pacific Ethanol Inc (NASDAQ:PEIX) showed a positive weekly performance of 10.29%.
Ocean Power Technologies, Inc. (Nasdaq:OPTT) announced that it intends to offer shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Ocean Power Technologies Inc (NASDAQ:OPTT) shares fell -6.17% in last trading session and ended the day on $3.80. OPTT return on equity ratio is recorded as -72.80% and its return on assets is -53.60%. Ocean Power Technologies Inc (NASDAQ:OPTT) yearly performance is 160.27%.
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that data from three studies related to its early stage scientific programs will be presented at the Annual Meeting of the American Association of Cancer Research (AACR) being held April 5-9, 2014 at the San Diego Convention Center in San Diego, CA. OXiGENE Inc (NASDAQ:OXGN) shares moved down -5.74% in last trading session and was closed at $3.61, while trading in range of $3.59-$3.81. OXiGENE Inc (NASDAQ:OXGN) year to date performance is 43.25%.
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) on Feb. 27, 2014 announced that it has entered into a share purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“LPC”) that will provide an initial investment in Oncolytics of US$1.0 million and make available additional periodic investments of up to US$25.0 million over a 30-month term (the “Financing”).Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) weekly performance is 1.67%. On last trading day company shares ended up $1.83. Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) distance from 50-day simple moving average is 7.28%. Analysts mean target price for the company is $7.28.